Carotid With Bivalirudin Angioplasty (COBRA)
This study is currently recruiting participants.
Verified March 2013 by Medstar Research Institute
Sponsor:
Medstar Research Institute
Information provided by (Responsible Party):
Medstar Research Institute
ClinicalTrials.gov Identifier:
NCT00812383
First received: December 18, 2008
Last updated: March 28, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Single center randomized clinical trial, to evaluate the safety and efficacy of carotid artery stenting using the RX ACCULINK™ Carotid Stent System with RX ACCUNET™ Embolic Protection System or PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System using Angiomax (bivalirudin)versus heparin as the anticoagulant for treatment of occlusive carotid artery disease in low and high risk patient cohorts.
| Condition | Intervention | Phase |
|---|---|---|
|
Carotid Artery Disease |
Device: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Carotid With Bivalirudin Angioplasty |
Resource links provided by NLM:
Further study details as provided by Medstar Research Institute:
Primary Outcome Measures:
- To evaluate clinical success (<50% residual stenosis at all treatment sites without death, myocardial infarction, stroke or major bleed) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To assess for complications including death, myocardial infarction, major or minor stroke, major or minor bleeding, and vascular complications. [ Time Frame: In hospital and 30 days ] [ Designated as safety issue: Yes ]
- To assess stent patency , and occurence of death or recurrent neurological events [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 380 |
| Study Start Date: | August 2003 |
| Estimated Primary Completion Date: | August 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Bivalirudin |
Device: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
|
| Active Comparator: Heparin |
Device: RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The patient must be at least 18 years of age.
- The patient must have a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as ≥50% stenosis for symptomatic patients or ≥80% stenosis for asymptomatic patients determined by carotid duplex ultrasound scan and/or carotid angiography.
- Female patients with child bearing potential must have a negative pregnancy test.
- The patient and the patient's physician must agree to have the patient return for a 30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated in the protocol.
- Reference vessel diameter ≥ 3.5 mm - ≤ 9.0 mm diameter.
Exclusion Criteria:
- The patient has had a recent (<4 weeks) disabling stroke or dementia with major neurologic deficit (stroke scales: Barthel <60, NIH >15, or Rankin >3) at pre-procedure neuro exam.
- The patient has had within four weeks of the treatment procedure an intracranial hemorrhage, hemorrhage stroke, major stroke, or any stroke with mass effect demonstrated on MRI or CT.
- The patient has a known allergy to heparin, bivalirudin, aspirin or to anti-platelet agents that prevents taking aspirin plus ticlopidine or aspirin plus clopidogrel.
- The patient has received fractionated or unfractionated heparin within 8 hours prior to the procedure.
- The patient has a history of prior life-threatening radiocontrast reaction that cannot be pre-treated.
- The patient has a history of bleeding diathesis or coagulopathy within 3 months.
- The patient is currently participating in another study protocol that may influence either procedure results or follow-up evaluations.
- Plasma/serum creatinine > 3.0 mg/dl at time of intervention.
- Hemodynamic instability at the time of intervention.
- Previous stent placement in the ipsilateral carotid distribution.
Angiographic Exclusion Criteria
- The patient has an intracranial tumor, or cerebral arterio-venous malformation(s) > 5mm, aneurysms or severe intracranial stenosis distal to target lesion.
- The patient has inaccessible intracranial arterial stenosis greater in severity than the extracranial internal carotid artery lesion.
- There is angiographic evidence of significant intra-luminal thrombus burden with presumed increased risk of plaque fragmentation and consequent distal embolization.
- There is total occlusion of the ipsilateral carotid artery treatment site with TIMI 0 flow characteristics.
- The reference segment diameter (internal carotid artery segment cephalad to the lesion) is less than 3 millimeters by operator visual estimate.
- The patient has peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding use of catheter-based techniques required for successful CSSA
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00812383
Contacts
| Contact: Lowell Satler, M.D. | 202-877-5975 |
Locations
| United States, District of Columbia | |
| Washington Hospital Center | Recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Lowell Satler, M.D. | |
| Principal Investigator: Lowell Satler, M.D. | |
Sponsors and Collaborators
Medstar Research Institute
More Information
No publications provided
| Responsible Party: | Medstar Research Institute |
| ClinicalTrials.gov Identifier: | NCT00812383 History of Changes |
| Other Study ID Numbers: | COBRA |
| Study First Received: | December 18, 2008 |
| Last Updated: | March 28, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Carotid Artery Diseases Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Bivalirudin Antithrombins |
Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anticoagulants Hematologic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013